Smoking and mental health - NCSCT

More documents

Recommendations

Info

Smoking and mental health 26 Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 2010;196:346. 27 Yousefi M, Folsom T, Fatemi H. A review of the efficacy and tolerability of varenicline in smoking cessation studies in subjects with schizophrenia. Journal of Addiction Research and Therapy 2011;S4:3045. 28 McEwen A, West R, McRobbie H. Effectiveness of specialist group treatment for smoking cessation vs. one-to-one treatment in primary care. Addictive Behaviors 2006;31:1650–60. 29 George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000;157:1835–42. 30 Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry 2006;163:1934–42. 31 Campion J, Hewitt J, Shiers D, Taylor D (2010) Pharmacy guidance on smoking and mental health. Forum for Mental Health in Primary Care. www.rcpsych.ac.uk/pdf/ Pharmacy_%20guidance%20for%20smoking%20and%20mental%20health%20Feb %202010.pdf [Accessed 20 February 2013] 32 Weiser M, Reichenberg A, Grotto I. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. American Journal of Psychiatry 2004;161:1219–23. 33 Williams JM, Ziedonis DM, Abanyie F. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia Research 2005;79:323–35. 34 Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Hospital and Community Psychiatry 2004;55:1064–6. 35 Evins A, Mays V, Rigotti N, et al. A pilot trial of bupropion added to cognitive behavioural therapy for smoking cessation in schizophrenia. Nicotine and Tobacco Research 2001;3:397–403. 36 Evins A, Cather C, Deckersbach T, et al. Double-blind, placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology 2005;25:218–25. 37 George T, Vessicchio J, Termine A, et al. A Placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 2002;52:53–61. 38 Evins A, Cather C, Culhane M, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Journal of Clinical Psychopharmacology 2007;27:380–6. 39 George T, Vessicchio J, Sacco K, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biological Psychiatry 2008;63:1092–6. 40 Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. British Medical Journal 2009;339:b3805. 41 Williams J, Anthenelli R, Morris C, et al. A randomised, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2012;73:654–60. 106 © Royal College of Physicians 2013
Smoking cessation interventions for individuals with mental disorders 5 42 Pachas G, Cather C, Pratt S, et al. Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. Journal of Dual Diagnosis 2012;8:117–25. 43 Weiner E, Bucholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a randomized double blind pilot study. Schizophrenia Research 2011;129:94–5. 44 Smith RC, Lindenmayer J, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research 2009;110:149–55. 45 Pfizer News and Media. New study with CHANTIX/CHAMPIX (varenicline) tablets suggests favourable benefit-risk profile in adult smokers with major depressive disorder, 2012. http://press.pfizer.com/press-release/new-study-chantixchampix-varenicline-tabletssuggests%C2%A0favorable-benefit-risk-profile-a [Accessed 20 February 2013] 46 MHRA. Stop Smoking Treatments. 2013. www.mhra.gov.uk/PrintPreview/ DefaultSplashPP/CON2031590?ResultCount = 10&DynamicListQuery = &Dynamic ListSortBy = xCreationDate&DynamicListSortOrder = Desc&DynamicListTitle = &PageNumber = 1&Title = ‘Stop%20smoking’%20treatments [Accessed 20 February 2013] 47 Food and Drug Administration. Information for Healthcare Professionals: Varenicline and Bupropion, 2009. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm [Accessed 20 February 2013] 48 Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine and Tobacco Research 2007;9:631–46. 49 Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine and Tobacco Research 2006;8:739–49. 50 Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. British Medical Journal 2009;338:b1024. 51 Wang D, Connock, Barton P, et al. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess 2008;12:1–156. 52 Royal College of Physicians. Harm reduction in nicotine addiction. Helping people who can’t quit. London: RCP, 2007. 53 National Institute for Clinical Excellence. Tobacco – Harm Reduction. Draft guidance. London: NICE 2012. 54 Dalack GW, Meador-Woodruff JH. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine and Tobacco Research 1999;1:53–7. 55 George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000;157:1835–42. 56 Ratschen E, Britton J, Doody G, McNeill A. Smoke-free policy in acute mental health wards: avoiding the pitfalls. General Hospital Psychiatry 2009;31:131–6. 57 Meyer T, Lockwood G, Sujie X, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013;108:203–10. 58 McDermott M, Marteau T, Hollands G, Hankins M, Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: a cohort study. British Journal of Psychiatry 2013;202:62–7. 59 Lycett D, Murphy M, Aveyard P. Associations between weight change over 8 years and baseline body mass index in a cohort of continuing and quitting smokers. Addiction 2011;106:188–96. © Royal College of Physicians 2013 107
Page 1 and 2:
PDF not for circulation Smoking and
Page 3 and 4:
Contents Members of the Tobacco Adv
Page 5 and 6:
Contents 4.4.3 Attention deficit hy
Page 7 and 8:
Contents 6.4.3 Staff knowledge 122
Page 9 and 10:
Contents 10.5 Tobacco policy and me
Page 11 and 12:
Contributors Anthony Aclet - Specia
Page 13 and 14:
Contributors Jill Williams - Associ
Page 15 and 16:
1 Mental disorders 1.1 What is a me
Page 17 and 18:
Mental disorders 1 1.3 Common menta
Page 19 and 20:
Mental disorders 1 1.4.4 Somatisati
Page 21 and 22:
Mental disorders 1 In addition to s
Page 23 and 24:
Mental disorders 1 not diagnosed un
Page 25 and 26:
Mental disorders 1 Similar to many
Page 27 and 28:
Mental disorders 1 12 Chang CK, Hay
Page 29 and 30:
Mental disorders 1 52 Young S, Toon
Page 31 and 32:
Smoking among people with mental di
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Neurobiological and behavioural mec
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70: Neurobiological and behavioural mec
Page 77 and 78: Epidemiology of the association bet
Page 99 and 100: Smoking cessation interventions for
Page 119: Smoking cessation interventions for
Page 125 and 126: 6 Population strategies to prevent
Page 127 and 128: Population strategies to prevent sm
Page 145 and 146: Smoking and mental disorders: speci
Page 171 and 172:
Smoking and mental disorders: speci
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
The economic cost of smoking in peo
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Ethical and legal aspects 9 pose co
Page 199 and 200:
Ethical and legal aspects 9 less an
Page 201 and 202:
Ethical and legal aspects 9 patient
Page 203 and 204:
10 Summary and conclusions 10.1 Smo
Page 205 and 206:
Summary and conclusions 10 10.4 Smo
Page 207 and 208:
Summary and conclusions 10 although
Page 209 and 210:
11 Key conclusions and recommendati
Page 211 and 212:
Key conclusions and recommendations
Page 213 and 214:
Page 215:
show all

Smoking and mental health - NCSCT

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?